JP2020505381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505381A5 JP2020505381A5 JP2019539814A JP2019539814A JP2020505381A5 JP 2020505381 A5 JP2020505381 A5 JP 2020505381A5 JP 2019539814 A JP2019539814 A JP 2019539814A JP 2019539814 A JP2019539814 A JP 2019539814A JP 2020505381 A5 JP2020505381 A5 JP 2020505381A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound
- solvate
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 81
- 150000003839 salts Chemical class 0.000 claims 43
- 239000012453 solvate Substances 0.000 claims 41
- 125000000623 heterocyclic group Chemical group 0.000 claims 37
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 14
- 125000004429 atom Chemical group 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 229910052805 deuterium Inorganic materials 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 150000001345 alkine derivatives Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 206010061598 Immunodeficiency Diseases 0.000 claims 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 230000007813 immunodeficiency Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 2
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000009766 Blau syndrome Diseases 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 2
- 208000003926 Myelitis Diseases 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000007887 Alphavirus Infections Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 201000003274 CINCA syndrome Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 206010061788 Corneal infection Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 241001475178 Dira Species 0.000 claims 1
- 208000021866 Dressler syndrome Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- 206010054261 Flavivirus infection Diseases 0.000 claims 1
- 206010053759 Growth retardation Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 241000876474 Sapho Species 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000010265 Sweet syndrome Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000024858 congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 231100000001 growth retardation Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 210000005227 renal system Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 201000005956 sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay Diseases 0.000 claims 1
- 230000037432 silent mutation Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- IYUXBZVMFGEWMU-ZTAGZOEFSA-N C/N=C\C(\S(NC(Nc1c(CCC2)c2cc2c1CCC2)=O)(=O)=O)=C(/NC1)\OC[C@@H]1OC Chemical compound C/N=C\C(\S(NC(Nc1c(CCC2)c2cc2c1CCC2)=O)(=O)=O)=C(/NC1)\OC[C@@H]1OC IYUXBZVMFGEWMU-ZTAGZOEFSA-N 0.000 description 1
- NGNWWCOPQFNQHT-UHFFFAOYSA-N O=C(Nc1c(CCC2)c2cc2c1CCC2)NS(c1c(C(CCC2)F)[n]2nc1)(=O)=O Chemical compound O=C(Nc1c(CCC2)c2cc2c1CCC2)NS(c1c(C(CCC2)F)[n]2nc1)(=O)=O NGNWWCOPQFNQHT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449431P | 2017-01-23 | 2017-01-23 | |
| US62/449,431 | 2017-01-23 | ||
| US201762492813P | 2017-05-01 | 2017-05-01 | |
| US62/492,813 | 2017-05-01 | ||
| PCT/US2018/014728 WO2018136890A1 (en) | 2017-01-23 | 2018-01-22 | Chemical compounds as inhibitors of interleukin-1 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505381A JP2020505381A (ja) | 2020-02-20 |
| JP2020505381A5 true JP2020505381A5 (cg-RX-API-DMAC7.html) | 2021-03-04 |
| JP7163293B2 JP7163293B2 (ja) | 2022-10-31 |
Family
ID=61189525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539814A Active JP7163293B2 (ja) | 2017-01-23 | 2018-01-22 | インターロイキン－１活性の阻害剤としての化学化合物 |
Country Status (21)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7163293B2 (ja) | 2017-01-23 | 2022-10-31 | ジェネンテック， インコーポレイテッド | インターロイキン－１活性の阻害剤としての化学化合物 |
| BR112019024831A2 (pt) | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
| BR112020000259A2 (pt) * | 2017-07-07 | 2020-07-14 | Inflazome Limited | novos compostos de sulfonamida-carboxamida |
| MX2020000911A (es) | 2017-07-24 | 2020-09-10 | Novartis Ag Star | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. |
| EP3668842A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019034696A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019034688A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| PE20200758A1 (es) * | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| PE20210050A1 (es) * | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3759077A1 (en) * | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759102A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166633A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| EP3788041A1 (en) | 2018-05-04 | 2021-03-10 | Inflazome Limited | Novel compounds |
| CA3104199A1 (en) * | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| EP3836917A1 (en) | 2018-08-15 | 2021-06-23 | Inflazome Limited | Novel sulfonamideurea compounds |
| GB201817038D0 (en) * | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) * | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2022505562A (ja) * | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| US12421223B2 (en) | 2018-11-13 | 2025-09-23 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2957692T3 (es) | 2018-11-13 | 2024-01-24 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| KR102858168B1 (ko) * | 2019-01-14 | 2025-09-10 | 자이두스 라이프사이언시즈 리미티드 | 신규 치환된 설포닐우레아 유도체 |
| CN113195469B (zh) * | 2019-02-19 | 2024-05-24 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| WO2020254697A1 (en) | 2019-06-21 | 2020-12-24 | Ac Immune Sa | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
| US12466800B2 (en) | 2019-07-17 | 2025-11-11 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) |
| EP3999179A1 (en) * | 2019-07-17 | 2022-05-25 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CN114401971A (zh) | 2019-08-16 | 2022-04-26 | 英夫拉索姆有限公司 | 用作nlrp3抑制剂的大环磺酰脲衍生物 |
| CN114302876A (zh) | 2019-09-06 | 2022-04-08 | 英夫拉索姆有限公司 | Nlrp3抑制剂 |
| EP4059930A4 (en) * | 2019-11-12 | 2024-03-20 | Chengdu Baiyu Pharmaceutical Co., Ltd. | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND ITS APPLICATION IN MEDICINE |
| IL294536A (en) * | 2020-01-22 | 2022-09-01 | Hoffmann La Roche | Sulfonimidamide compounds as nlrp3 modulators |
| US20230121952A1 (en) | 2020-02-18 | 2023-04-20 | Inflazome Limited | Compounds |
| KR20220154165A (ko) * | 2020-03-16 | 2022-11-21 | 조마젠 바이오사이언시즈 엘티디 | Nlrp3 조절제 |
| AU2021248641A1 (en) | 2020-04-03 | 2022-10-27 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| AU2021265167A1 (en) * | 2020-04-30 | 2023-01-19 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| EP4168395A1 (en) | 2020-06-19 | 2023-04-26 | AC Immune SA | Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway |
| CN114539256B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
| CN114516878B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
| CN115894478B (zh) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | 一种新型吡啶并吡唑类杂环化合物及其应用 |
| WO2023116812A1 (zh) * | 2021-12-22 | 2023-06-29 | 瑞石生物医药有限公司 | 一种磺酰脲类化合物 |
| EP4452972A1 (en) | 2021-12-22 | 2024-10-30 | AC Immune SA | Dihydro-oxazol derivative compounds |
| WO2023211929A1 (en) * | 2022-04-25 | 2023-11-02 | Vanderbilt University | Probes and methods for targeted visualization of nlrp3 inflammasomes |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| IL317984A (en) | 2022-07-14 | 2025-02-01 | Ac Immune Sa | History of Pyrrolotriazine and Imidazotriazine as Modulators of the NLRP3 Inflammasome Pathway |
| KR20250044368A (ko) | 2022-07-28 | 2025-03-31 | 에이씨 이뮨 에스에이 | 신규 화합물 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| US20250326772A1 (en) | 2024-04-19 | 2025-10-23 | Kyorin Pharmaceutical Co., Ltd. | Mrgprx2 antagonists, pharmaceutical composition including mrgprx2 antagonist, and method of treating mrgprx2-mediated disease or disorder |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE69722663T2 (de) | 1997-01-29 | 2004-04-29 | Pfizer Inc. | Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität |
| AU6464400A (en) | 1999-09-14 | 2001-04-17 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| AU2002341321A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| JP6152643B2 (ja) | 2010-02-22 | 2017-06-28 | 株式会社ＡｓｋＡｔ | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 |
| KR20140075698A (ko) * | 2011-09-02 | 2014-06-19 | 교와 핫꼬 기린 가부시키가이샤 | 케모카인 수용체 활성 조절제 |
| EP2999691A4 (en) * | 2013-05-21 | 2017-02-08 | Virginia Commonwealth University | Cryopyrin inhibitors for preventing and treating inflammation |
| ME03737B (me) * | 2015-02-16 | 2021-01-20 | Univ Queensland | Sulfoniluree i srodna jedinjenja i njihova upotreba |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| CN109071454B (zh) | 2016-02-16 | 2023-02-17 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| WO2017184624A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| JP7163293B2 (ja) | 2017-01-23 | 2022-10-31 | ジェネンテック， インコーポレイテッド | インターロイキン－１活性の阻害剤としての化学化合物 |
| BR112019024831A2 (pt) | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| BR112020000259A2 (pt) | 2017-07-07 | 2020-07-14 | Inflazome Limited | novos compostos de sulfonamida-carboxamida |
| WO2019034686A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019034688A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| EP3668842A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019034696A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| PE20200758A1 (es) * | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| CN112584899A (zh) | 2018-07-03 | 2021-03-30 | 诺华股份有限公司 | Nlrp调节剂 |
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CA3104199A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| EP3836917A1 (en) | 2018-08-15 | 2021-06-23 | Inflazome Limited | Novel sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
-
2018
- 2018-01-22 JP JP2019539814A patent/JP7163293B2/ja active Active
- 2018-01-22 MY MYPI2019004010A patent/MY197636A/en unknown
- 2018-01-22 MA MA055695A patent/MA55695A/fr unknown
- 2018-01-22 EP EP18704341.9A patent/EP3571187B1/en active Active
- 2018-01-22 MA MA047308A patent/MA47308A/fr unknown
- 2018-01-22 CN CN201880014694.0A patent/CN110366549A/zh active Pending
- 2018-01-22 UA UAA201907805A patent/UA126675C2/uk unknown
- 2018-01-22 EP EP20212018.4A patent/EP3851434A1/en not_active Withdrawn
- 2018-01-22 CA CA3047336A patent/CA3047336A1/en active Pending
- 2018-01-22 WO PCT/US2018/014728 patent/WO2018136890A1/en not_active Ceased
- 2018-01-22 TW TW107102246A patent/TW201837021A/zh unknown
- 2018-01-22 SG SG11201906373VA patent/SG11201906373VA/en unknown
- 2018-01-22 KR KR1020197024262A patent/KR20190111068A/ko not_active Abandoned
- 2018-01-22 AU AU2018210525A patent/AU2018210525B2/en not_active Ceased
- 2018-01-22 CR CR20190356A patent/CR20190356A/es unknown
- 2018-01-22 MX MX2019008592A patent/MX2019008592A/es unknown
- 2018-01-22 PE PE2019001474A patent/PE20191615A1/es unknown
- 2018-01-22 BR BR112019014549-4A patent/BR112019014549A2/pt not_active IP Right Cessation
-
2019
- 2019-07-09 PH PH12019501611A patent/PH12019501611A1/en unknown
- 2019-07-10 IL IL267961A patent/IL267961B2/en unknown
- 2019-07-15 CL CL2019001988A patent/CL2019001988A1/es unknown
- 2019-07-16 US US16/513,621 patent/US11040985B2/en active Active
- 2019-08-21 CO CONC2019/0009036A patent/CO2019009036A2/es unknown
-
2021
- 2021-01-25 US US17/157,749 patent/US20210395268A1/en not_active Abandoned
-
2022
- 2022-03-03 US US17/686,183 patent/US11702428B2/en active Active